[go: up one dir, main page]

TNSN00117A1 - Neurim pharmaceuticals eec ltd - Google Patents

Neurim pharmaceuticals eec ltd

Info

Publication number
TNSN00117A1
TNSN00117A1 TNTNSN00117A TNSN00117A TNSN00117A1 TN SN00117 A1 TNSN00117 A1 TN SN00117A1 TN TNSN00117 A TNTNSN00117 A TN TNSN00117A TN SN00117 A TNSN00117 A TN SN00117A TN SN00117 A1 TNSN00117 A1 TN SN00117A1
Authority
TN
Tunisia
Prior art keywords
eec
melatonin
treatment
symptoms
neurim
Prior art date
Application number
TNTNSN00117A
Other languages
English (en)
Original Assignee
Neurim Pharmaceuticals Eec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals Eec Ltd filed Critical Neurim Pharmaceuticals Eec Ltd
Publication of TNSN00117A1 publication Critical patent/TNSN00117A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L’INVENTION SE RAPPORTE A UNE METHODE POUR LA PREVENTION OU LE TRAITEMENT DES SYMPTOMES DE LA DYSKINESIE TARDIVE CHEZ UN PATIENT, EN ADMINISTRANT UNE QUANTITE EFFICACE DE MELATONINE A CETTE FIN, ET A UNE COMPOSITION PHARMACEUTIQUE QUI CONTIENT AU MOINS UN COMPOSE NEUROLEPTIQUE EN QUANTITE EFFICACE POUR EXERCER UN EFFET NEUROLEPTIQUE CHEZ UN PATIENT NECESSITANT UN TEL TRAITEMENT, ET LA MELATONINE EN QUANTITE EFFICACE POUR AMELIORER OU PREVENIR LE DEVELOPPEMENT DES SYMPTOMES DE LA DYSKINESIE TARDIVE.
TNTNSN00117A 1999-05-27 2000-05-26 Neurim pharmaceuticals eec ltd TNSN00117A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL13017199A IL130171A (en) 1999-05-27 1999-05-27 Melatonin for use in preventing and treating tardive dyskinesia, pharmaceutical preparations containing it and its use in the manufacture of medicines

Publications (1)

Publication Number Publication Date
TNSN00117A1 true TNSN00117A1 (fr) 2005-11-10

Family

ID=11072852

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN00117A TNSN00117A1 (fr) 1999-05-27 2000-05-26 Neurim pharmaceuticals eec ltd

Country Status (30)

Country Link
US (1) US6566389B1 (fr)
EP (1) EP1183024A4 (fr)
JP (1) JP2003500446A (fr)
KR (1) KR20020015329A (fr)
CN (1) CN1176652C (fr)
AR (1) AR036321A1 (fr)
AU (1) AU775520B2 (fr)
BG (1) BG106234A (fr)
BR (1) BR0017329A (fr)
CA (1) CA2374129A1 (fr)
CZ (1) CZ20014190A3 (fr)
EA (1) EA004057B1 (fr)
EE (1) EE200100623A (fr)
HK (2) HK1046089A1 (fr)
HU (1) HUP0201405A3 (fr)
IL (1) IL130171A (fr)
IS (1) IS6172A (fr)
MX (1) MXPA01012040A (fr)
NO (1) NO319421B1 (fr)
NZ (1) NZ515866A (fr)
PE (1) PE20010129A1 (fr)
PL (1) PL351885A1 (fr)
SK (1) SK16402001A3 (fr)
TN (1) TNSN00117A1 (fr)
TR (1) TR200103418T2 (fr)
TW (1) TWI236906B (fr)
UA (1) UA71968C2 (fr)
UY (1) UY26171A1 (fr)
WO (1) WO2000072843A1 (fr)
ZA (1) ZA200110436B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US7799817B2 (en) * 2004-02-20 2010-09-21 Lifescape Biosciences Inc Compositions and methods for sleep regulation
CN1299680C (zh) * 2005-08-29 2007-02-14 陈彦方 一种治疗失眠的黑白制剂
US7494674B2 (en) 2006-09-22 2009-02-24 Lapointe Andrew T Nutraceutical with tart cherries and method of treatment therewith
WO2008116004A2 (fr) 2007-03-19 2008-09-25 Vita Sciences, Llc Timbre transdermique et méthode for d'administration de vitamine b12
WO2008128166A1 (fr) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Dérivés deutériés de composés 4-(6-fluoro-1,2-benzisoxazol-3-yl) pipéridine
US20100256197A1 (en) * 2009-04-02 2010-10-07 Silver Eagle Labs Nv, Llc Nicotine Dissolving Film With Or Without Menthol
US20100256215A1 (en) * 2009-04-02 2010-10-07 Silver Eagle Labs Nv, Llc Menthol-Melatonin Dissolving Film
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
FR3000896B1 (fr) 2013-01-14 2016-08-26 Philippe Perovitch Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691324A (en) * 1994-01-14 1997-11-25 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
US6469044B1 (en) * 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
AUPO588297A0 (en) * 1997-03-26 1997-04-24 Luminis Pty Limited Mediation in melatonin production

Also Published As

Publication number Publication date
IL130171A (en) 2004-06-01
AR036321A1 (es) 2004-09-01
MXPA01012040A (es) 2003-09-04
WO2000072843A1 (fr) 2000-12-07
NZ515866A (en) 2003-05-30
BR0017329A (pt) 2003-07-29
TWI236906B (en) 2005-08-01
SK16402001A3 (sk) 2002-04-04
EE200100623A (et) 2003-02-17
HK1047048B (zh) 2005-05-27
KR20020015329A (ko) 2002-02-27
AU4775600A (en) 2000-12-18
IL130171A0 (en) 2000-06-01
CZ20014190A3 (cs) 2002-05-15
JP2003500446A (ja) 2003-01-07
CN1176652C (zh) 2004-11-24
EA200101240A1 (ru) 2002-06-27
IS6172A (is) 2001-11-22
HK1046089A1 (zh) 2002-12-27
HK1047048A1 (en) 2003-02-07
BG106234A (bg) 2002-08-30
EA004057B1 (ru) 2003-12-25
NO20015738L (no) 2002-01-25
PE20010129A1 (es) 2001-04-27
TR200103418T2 (tr) 2004-12-21
US6566389B1 (en) 2003-05-20
HUP0201405A3 (en) 2003-11-28
UY26171A1 (es) 2000-12-29
AU775520B2 (en) 2004-08-05
EP1183024A1 (fr) 2002-03-06
NO319421B1 (no) 2005-08-08
HUP0201405A2 (en) 2002-08-28
PL351885A1 (en) 2003-06-30
CN1352556A (zh) 2002-06-05
UA71968C2 (en) 2005-01-17
CA2374129A1 (fr) 2000-12-07
ZA200110436B (en) 2004-03-31
EP1183024A4 (fr) 2007-02-28
NO20015738D0 (no) 2001-11-26

Similar Documents

Publication Publication Date Title
TNSN00117A1 (fr) Neurim pharmaceuticals eec ltd
TNSN96104A1 (fr) Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
MX9705235A (es) Inhibidores de calpaina y/o catepsina b de oxazolidina substituida.
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
EA200100872A1 (ru) Композиция валдекоксиба
MA27565A1 (fr) Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur
TNSN99172A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN95046A1 (fr) Formes posologiques d'azithromycine pour le traitement d'infections microbiennes
BR0208563A (pt) composições de n-acetilcisteìna e métodos para o tratamento e prevenção de toxidade de droga
TNSN01017A1 (fr) Compositions comprenant un antibiotique azalide, et procedes pour leur preparation
EA200000718A1 (ru) Композиции целекоксиба
BE2012C005I2 (fr)
BRPI0413326A (pt) métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
WO2003055979A3 (fr) Anticorps se liant à blys selon un mode immunospécifique
EA200500782A1 (ru) Лечение геморрагического шока
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
TNSN99001A1 (fr) Indoles 2,3-substitues servant d'agents anti-inflammatoires et analgesiques
DE60238391D1 (de) Azole als malonyl-coa decarboxylase hemmer verwendbar als modulatoren des metabolismus
EA200501019A1 (ru) Противораковое лекарственное средство, фармацевтическая композиция и способ ингибирования размера опухоли (варианты) на его основе
BRPI0413404A (pt) composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif
WO2003105753A3 (fr) Procedes et compositions pour la greffe de boucles fonctionnelles dans une proteine